SajeveSamuelThomasMD

Gastrointestinal Cancer, Melanoma, Sarcoma

Physician

Overview of Dr. Thomas

Dr. Sajeve Thomas is an oncologist in Orlando, FL and is affiliated with Orlando Health Orlando Regional Medical Center. He received his medical degree from University of Florida College of Medicine and has been in practice 12 years. He is one of 74 doctors at Orlando Health Orlando Regional Medical Center who specialize in Oncology. He has more than 10 publications and over 500 citings.

Office
1400 S Orange Ave
Orlando, FL 32806
Book by Phone+1(321) 730-2087

Education & Training

University of FloridaFellowship, Hematology and Medical Oncology, 2008 - 2011
University of South Florida MorsaniResidency, Internal Medicine, 2005 - 2008
University of Florida College of MedicineClass of 2005

Certifications & Licensure

FL State Medical License 2007 - 2026
MT State Medical License 2024 - 2026

Clinical Trials

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Start of enrollment: 2011 Apr 01
Terminated
Phase 3
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer Start of enrollment: 2012 Dec 17
Completed
Phase 1, Phase 2
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer Start of enrollment: 2013 May 01
Completed
Phase 3
A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) Start of enrollment: 2022 May 23
Active, not recruiting
Phase 2, Phase 3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

3 citations
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.
Omid Hamid, Karl D Lewis, Amy Weise, Meredith McKean, Kyriakos P Papadopoulos
Journal of Clinical Oncology. 2024-08-20
77 citations
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Jeffrey S Weber, Matteo S Carlino, Adnan Khattak, Tarek Meniawy, George Ansstas
Lancet. 2024-02-17
77 citations
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immu...
Jason Chesney, Karl D Lewis, Harriet Kluger, Omid Hamid, Eric Whitman
Journal for Immunotherapy of Cancer. 2022-12-01

Press Mentions

Cancer Specialists in Florida See Dramatic Results with New Clinical TrialNovember 22nd, 2021
Iovance: Assessing the Potential for Further UpsideMay 20th, 2019